Evidence map›Paper›PMID 31300997›Full record

SynthesisEndocrine pathology2019

A Systematic Review and Meta-Analysis of the Diagnostic Performance of BRAF V600E Immunohistochemistry in Thyroid Histopathology.

Ranjit Singarayer, Ozgur Mete, Laure Perrier, Lehana Thabane, Sylvia L Asa, Stan Van Uum, Shereen Ezzat, David P Goldstein, Anna M Sawka

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Endocrine pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Ranjit SingarayerThyroid Fellow, University of Toronto, Toronto, Canada.
Ozgur MeteDepartment of Pathology, University Health Network and University of Toronto, Toronto, Canada.
Laure PerrierUniversity of Toronto Libraries, University of Toronto, 130 St. George St, Toronto, Ontario, Canada.
Lehana ThabaneDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Sylvia L AsaDepartment of Pathology, University Health Network and University of Toronto, Toronto, Canada.
Stan Van UumDivision of Endocrinology, Western University, London, Ontario, Canada.
Shereen EzzatDepartment of Endocrine Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
David P GoldsteinDepartment of Otolaryngology, Head and Neck Surgery, University Health Network and University of Toronto, Toronto, Canada.
Anna M SawkaDivision of Endocrinology, University Health Network and University of Toronto, Toronto, Canada. sawkaam@yahoo.com.
University of Toronto · CAPrincess Margaret Cancer Centre · CAMcMaster University · CAToronto General Hospital · CAUniversity Health Network · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunohistochemistry (IHC) in evaluating thyroid surgical specimens may facilitate diagnostic and prognostic evaluation, with potential therapeutic implications. We performed a systematic review and meta-analysis examining the analytic validity of IHC in detecting BRAFV600E mutations in thyroid cancer (primary or metastatic). We screened citations from three electronic databases (until December 20, 2018), supplemented by a hand search of authors' files and cross-references of reviews. Citations and full-text papers were independently reviewed in duplicate, and consensus was achieved on inclusion of papers. Two reviewers independently critically appraised and abstracted data from included papers. Random-effect meta-analyses were conducted for sensitivity and specificity estimates. We reviewed 1499 unique citations and 93 full-text articles. We included 1 systematic review and 30 original articles. The published review (from 2015) needed to be updated as there were multiple subsequent original studies. The pooled sensitivity of IHC in detecting a BRAFV600E mutation was 96.8% (95% confidence interval [CI] at 94.1%, 98.3%) (29 studies, including 2659 BRAFV600E mutant tumors). The IHC pooled specificity was 86.3% (95% CI 80.7%, 90.4%) (28 studies, including 1107 BRAFV600E wild-type specimens). These meta-analyses were subject to statistically significant heterogeneity, partly explained by antibody type (sensitivity and specificity) and tissue/tumor type (specificity). In conclusion, BRAF IHC is highly sensitive and reasonably specific in detecting the BRAFV600E mutation; however, there is some variability in analytic performance.

Indexed as

Mutation, MissenseAmino Acid SubstitutionBiomarkers, TumorCytodiagnosisDiagnosis, DifferentialGlutamic AcidHumansImmunohistochemistryPredictive Value of TestsPrognosisProto-Oncogene Proteins B-rafSensitivity and SpecificityThyroid GlandThyroid NeoplasmsThyroid NoduleValineBiomarkers, TumorBRAF protein, humanGlutamic AcidProto-Oncogene Proteins B-rafValineBRAFV600EDiagnostic accuracyMeta-analysisPapillary thyroid carcinomaSystematic reviewThyroid cancer

Identifiers

PMID31300997
OpenAlexW2960328152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.